- Research article
- Open Access
High-fat diet accelerates progression of osteoarthritis after meniscal/ligamentous injury
Arthritis Research & Therapyvolume 13, Article number: R198 (2011)
Increasing obesity and type 2 diabetes, in part due to the high-fat (HF) Western diet, parallels an increased incidence of osteoarthritis (OA). This study was undertaken to establish a causal relation between the HF diet and accelerated OA progression in a mouse model and to determine the relative roles of weight gain and metabolic dysregulation in this progression.
Five-week-old C57BL/6 mice were placed on HF (60% kcal) or low-fat (lean, 10% kcal) diets for 8 or 12 weeks before transecting the medial collateral ligament and excising a segment of the medial meniscus of the knee to initiate OA. One group was switched from lean to HF diet at the time of surgery.
Body weight of mice on the HF diet peaked at 45.9 ± 2.1 g compared with 29.9 ± 1.8 g for lean diets, with only those on the HF becoming diabetic. Severity of OA was greater in HF mice, evidenced by the Osteoarthritis Research Society International (OARSI) histopathology initiative scoring method for mice and articular cartilage thickness and area. To assess the importance of weight gain, short- and long-term HF diets were compared with the lean diet. Short- and long-term HF groups outweighed lean controls by 6.2 g and 20.5 g, respectively. Both HF groups became diabetic, and OA progression, evidenced by increased OARSI score, decreased cartilage thickness, and increased osteophyte diameter, was comparably accelerated relative to those of lean controls.
These results demonstrate that the HF diet accelerates progression of OA in a type 2 diabetic mouse model without correlation to weight gain, suggesting that metabolic dysregulation is a comorbid factor in OA-related cartilage degeneration.
Decreased physical activity and the consumption of a high-fat Western diet have contributed to a worldwide epidemic of obesity and associated type 2 diabetes . As a result, the incidence of cardiovascular disease, hypertension, cancer, nonalcoholic fatty liver disease, stroke, and other secondary complications is anticipated to be negatively affected [2, 3]. One additional consequence of this epidemic is an increased incidence of osteoarthritis (OA) in both weight-bearing and non-weight-bearing joints [4, 5], with more than 50% of those with diabetes having some form of arthritis . In the United States, 52.1% of patients receiving knee replacements in 2005 were obese . In Canada, 87% were either obese or overweight . A morbidly obese patient is 33 times more likely to require knee replacement than is an individual of normal body mass . Despite these statistics, current knowledge does not adequately explain the relative contribution to OA of biomechanical changes resulting from increased body mass versus the metabolic dysfunction in obesity. Although it is widely accepted that the increased biomechanical stresses on the weight-bearing diarthrodial joints due to obesity can initiate and accelerate the OA disease process , the potential influence of metabolic dysfunction on the progression of OA is receiving increasing attention [9, 10].
Increased dietary fat, as consumed in Western diets, can contribute to both obesity and the metabolic dysfunction that is associated with insulin resistance/type 2 diabetes. Surplus dietary fat is deposited in adipose tissue as well as in skeletal muscle, heart, and liver. As this fat burden increases, adverse effects on systemic metabolism increase . The current model of insulin resistance of obesity as a proinflammatory state is based in part on the observation that adipose tissue in obese individuals and animal models contains increased numbers of activated macrophages that release proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-α [12, 13]. These cytokines act both locally on adipocytes and systemically to impair insulin action in insulin-target tissues [11, 14, 15]. Metabolism of the abundant circulating free fatty acids in the high-fat diet can also lead to oxidative stress in cells, formation of lipid peroxides, and subsequent oxidative damage to DNA, RNA, and proteins [16–18]. Oxidative stress has been more specifically shown to inhibit insulin-receptor signaling pathways in cells, at least in part through activation of the stress kinases JNK and p38 and to impair mitochondrial function [19, 20]. The net effect of the proinflammatory state and tissue oxidative stress is a systemic metabolic dysfunction that defines the metabolic syndrome and type 2 diabetes that are associated with high-fat diets and obesity.
Although it is widely accepted that the increased biomechanical stress associated with obesity contributes to the initiation/progression of OA [21–23], the importance of type 2 diabetes-related systemic metabolic dysregulation in the OA disease process has not been delineated. To begin to address this question, an animal model was used to test the hypothesis that HF diet-induced obesity and associated glucose intolerance/insulin resistance accelerate the progression of osteoarthritis after meniscal/ligamentous injury (MLI). This model was subsequently used to determine whether marked obesity is required for the HF diet to accelerate OA.
Materials and methods
Male C57BL/6J mice purchased from Jackson Laboratories (Bar Harbor, ME) were housed five per cage in a microisolator room on a 12-hour light/dark cycle at the University of Rochester. Mice were placed on a high-fat (60% kcal, D12492) or low-fat (10% kcal, D12450B) diet at 5 weeks of age (Open Source Diets, Research Diets Inc., New Brunswick, NJ). After 8 or 12 weeks on the diet, mice were anesthetized by using intraperitoneal (IP) injection of 60 mg/kg ketamine and 4 mg/kg xylazine, and the medial collateral ligament of the right hindlimb was transected, and a segment of the medial meniscus detached and excised by using a surgical method  that we have established in our laboratory . It should be noted that this model of injury, termed MLI, leads to posttraumatic OA that is detectable by 4 weeks after injury and progresses over a 4-month period, similar to that seen in the DMM model of posttraumatic OA . The contralateral limb was sham-operated and represented the experimental control. Pre- and postsurgery mice were provided analgesia (intraperitoneal (IP) injection of 0.5 mg/kg buprenorphine) every 12 hours for 72 hours. Before killing mice at monthly intervals, the mice were fasted overnight, weighed, and tail-vein blood samples were taken for blood glucose measurements by using One Touch glucose meters (Lifescan, Inc., Milpitas, CA). Hemoglobin A1c measurements were made on tail-vein blood samples by using a Bayer DCA 2000 HgbA1C analyzer (Deerfield, IL). The assay is based on monoclonal antibody detection of the glycated amino terminus of the β-chain of human hemoglobin. The University Committee on Animal Resources approved all protocols.
Tissue harvest and histologic analysis of OA progression
After establishment of deep anesthesia by using IP injection of 60 mg/kg ketamine and 4 mg/kg xylazine, mice were killed via cardiac perfusion by using 10 ml of phosphate-buffered saline followed by 10% neutral buffered formalin. Isolated knee joints were fixed for 3 days in 10% neutral buffered formalin at 23°C. Samples were decalcified for 2 weeks in 10% wt/vol EDTA and embedded in paraffin. Three-micrometer-thick sagittal sections from the medial joint compartment of the right knee were cut on a microtome and mounted on positively charged slides, baked at 60°C for 30 minutes, deparaffinized in xylene, and rehydrated in decreasing concentrations of ethanol.
Mouse knee-joint sections were stained with both Safranin O-fast green and Alcian blue-hematoxylin to allow visualization of cartilage tissue. Semiquantitative histopathologic grading of Alcian blue-stained knee-joint cartilage was performed on sagittal sections by using a murine scoring system established by the OARSI histopathology initiative , in which 0 = normal cartilage, 0.5 = loss of proteoglycan stain without cartilage damage, 1 = mild superficial fibrillation, 2 = fibrillation and/or clefting extending below the superficial zone, 3 = mild (< 25%) loss of cartilage, 4 = moderate (25% to 50%) loss of cartilage, 5 = severe (50% to 75%) loss of noncalcified cartilage, and 6 = eburnation with > 75% loss of cartilage.
Quantification of cartilage morphologic features
After histologic grading, Alcian blue-stained sagittal sections were evaluated for cartilage area and thickness by using OsteoMeasure software (OsteoMetrics, Decatur, GA), as previously described . Articular cartilage was defined as the area from the joint surface to the junction of the deep zone of the cartilage with the subchondral bone, including the entire surface from the anterior to the posterior edges of both the tibia and the femur. Cartilage area was quantified in each section by using an area-calculating algorithm in the software, as we previously described . Similarly, tibial cartilage thickness was analyzed at the center of the tibial plateau. Osteophytes were positively identified by using the following criteria: the osteophyte (a) protruded into the joint space, (b) contained hypertrophic chondrocytes, and (c) displayed evidence of calcification. Histologic assessment of osteophytes was performed on each slide by using a digital projection at ×100 magnification. The largest cross-sectional dimension of the osteophyte was measured, as was the perpendicular dimension. These two determinations were averaged. Where multiple osteophytes were detected, the mean of the average osteophyte diameters was recorded. All three parameters (thickness, area, osteophyte size) were determined and averaged among all sections. Each diet group contained five to eight mice, with three sections from each joint being analyzed in the histologic grading and histomorphometric analyses.
Micro-computed tomography (micro-CT) evaluation of mouse knee joints
Before histologic processing, knee joints were evaluated with micro-CT by using a Scanco vivaCT 40 scanner with 55-kVp source (Scanco USA, Inc., Wayne, PA). Joints were scanned at a resolution of 12 μm, with a slice increment of 10 μm. Images from each group were reconstructed at identical thresholds to allow 3-dimensional structural rendering of each joint. Analysis of bone volume was performed on selected regions between the femoral and tibial growth plates.
Results are expressed as mean values ± SEM. Statistical analysis was performed by using StatView 5 software (SAS Institute, Cary, NC). Data were tested for normality by using the Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefor P value). Experimental means were compared by using ANOVA; sample means from three or more groups were compared, and the Fisher protected least significant differences test was used for comparisons between pairs of groups. A calculated P value of less than 0.05 was considered significant when comparing between-group differences.
Five-week-old C57BL/6 mice were placed on either an HF diet representing 60% of total dietary kcal or an LF (lean) diet with 10% of kilocalories derived from fat. The HF diet has been shown to cause hyperglycemia and insulin resistance in this strain of mice . After 8 weeks, mice on the HF diet weighed 29% more than those on the lean diet (30.9 ± 0.9 g versus 23.9 ± 0.6 g; P < 0.0001; Figure 1a). Fasting blood glucose levels were in the diabetic range only for the HF group (182.3 ± 10.5 mg/dl; Figure 1B), confirming a dysmetabolic state associated with the HF diet.
Progression to severe OA is typically observed within 5 months by using the meniscal-ligamentous injury (MLI) technique . With the objective to determine whether the HF diet with its associated type 2 diabetic phenotype accelerates OA progression, mice from each dietary group (n = 4 to 9) were killed at monthly intervals out to 4 months after MLI surgery. Both groups gained weight over this 4-month period, with the HF group becoming markedly obese, with a peak weight of 45.9 ± 2.1 g compared with only 29.9 ± 1.8 g (P < 0.0001) for the lean group (Figure 1a). As expected, the HF group was diabetic (fasting blood glucose greater than 125 mg/dl), with peak levels of 288.8 ± 21.4 mg/dl at 4 months (Figure 1b). Histologic analysis of the articular cartilage at the 4-month time point revealed increased fibrillation, clefting, and decreased proteoglycan staining in response to MLI. These changes were more pronounced in the HF group (P < 0.01; Figure 2a) with major loss of cartilage. In some cases, this loss progressed nearly to the subchondral bone. No significant cartilage loss was observed in sham-operated knees of either HF or lean groups, with only occasional superficial zone fibrillation.
A progressive worsening of OA from 2 to 4 months was demonstrated in both diet groups, with the score for OA severity being significantly higher for the HF group at each of these time points (Figure 2b). Data for lean mice at month 1 indicate an unexpectedly advanced stage of OA for that time point. The explanation for this aberrant data point is not clear. With the OARSI score, the HF group on average had 25% to 50% loss of articular cartilage at 2 months (score of 4), whereas the lean group had less than 25% loss of articular cartilage at this same time point (score of 3; P < 0.01). As expected, the sham controls had scores of 1 or less, representing only occasional superficial zone fibrillation, even at 4 months (data not shown).
Histomorphometric analysis of the articular cartilage in the lean and HF groups over the 4-month time course confirmed the accelerated loss of articular cartilage in the HF diet group. Articular cartilage thickness on the tibial plateau progressively decreased in both groups but was approximately 40% to 50% thinner in the HF group between 2 and 4 months after MLI (Figure 2c). Similarly, total articular cartilage area, representing the combined cartilage areas of the femur and tibia, decreased progressively with the most marked difference between lean and HF diets being observed at the 4-month time point (Figure 2d). At this time point, cartilage area in the HF group had decreased by an additional 35% relative to lean controls (P < 0.01).
In the preceding experiments, the HF-fed mice at the later time points were markedly obese in consequence of a 6-month diet protocol that included 2 months of the HF diet before the initiation of OA with MLI. To determine whether this marked increase in body weight was primarily responsible for the accelerated progression of OA with HF feeding, two HF diet protocols were compared. One group of mice (n = 6) was fed an HF diet for 3 months before MLI to establish obesity before initiation of OA. In a second group (n = 8), an HF diet was begun only at the initiation of OA. As a result of beginning the HF diet at the time of MLI, this group of mice demonstrated only a modest increase in body weight relative to the lean diet controls (n = 7) (Figure 3a). This contrasts with the long-term HF diet group, which again attained a marked obese body weight that was 80% above that of lean mouse controls. Despite the modest weight gain, the short-term HF group displayed metabolic dysfunction, as indicated by fasting hyperglycemia at 1-, 2-, and 3-month time points, although levels were less than those of the long-term HF group. Values at 3 months are shown (Figure 3b). An additional marker for a dysmetabolic state, hemoglobin A1c, a measure of average blood glucose levels over the preceding 3-month period , was nearly equally elevated in the two HF groups (Figure 3c). Note that the absolute hemoglobin A1c values were less than those of humans, for whom this immunoassay-based test is designed. These results indicate that the short-term HF diet produced metabolic dysfunction without requiring marked obesity or the extended 3-month period on the HF diet before the MLI surgery.
Histologic analysis of the progression of OA at 3 months after MLI confirmed that a long-term HF diet was again associated with accelerated OA progression, with major loss of cartilage relative to the lean controls. In some cases, this loss progressed nearly to the subchondral bone. Importantly, the short-term HF diet group had an equally accelerated progression of OA when compared with the long-term HF group (Figure 4a). No significant cartilage loss was observed in sham-operated knees of either HF or lean groups, with only occasional superficial zone fibrillation. These observations were confirmed by comparably higher osteoarthritis grades for the HF groups relative to the lean controls, as assessed by the OARSI scoring method (P < 0.05; Figure 4b). It should be noted that the accelerated cartilage degeneration occurred in the short-term HF group despite the absence of marked obesity. In agreement with the OARSI scoring and supporting the idea that marked obesity is not required for acceleration of cartilage degeneration in mice fed an HF diet, tibial plateau articular cartilage thicknesses were 25% to 50% lower in the two HF groups compared with the lean group (Figure 4c). Cartilage-area determination supported the thickness data by demonstrating similar trends toward decreased area in both HF diet groups relative to mice fed the lean diet (data not shown). These results indicate that accelerated progression of OA in mice on an HF diet is associated with a diabetic metabolic phenotype, does not correlate with degree of weight gain, and does not require prolonged exposure to the HF diet.
Quantitative micro-CT analysis of knee joints at the 3-month time point showed increased bone volume in the MLI knees relative to sham-treated controls, consistent with OA-like subchondral sclerosis and joint/periarticular mineralization. Only differences in the HF-diet groups, however, were statistically significant (P < 0.01; Figure 5a).
Regarding enhanced joint and periarticular mineralization specifically, 3-dimensional reconstructions of the raw micro-CT data revealed a more progressive meniscal calcification and a suggestion of increased presence of osteophytes in both high-HF groups relative to the lean diet controls (Figure 5b). To investigate the possibility that HF diets promote the formation of osteophytes, all histologic slides were evaluated for the presence and size of osteophytes on the tibial surface. The blinded analysis revealed osteophytes in essentially all MLI-injured knees from all diet groups (Figure 6a). Importantly, not only was the size of the osteophytes greater in both HF-diet groups (P < 0.01), but they also were of comparable size in the short-term and long-term HF groups (Figure 6b). Interestingly, 30% of sham knees from HF-diet mice contained small osteophytes (Figure 6c), and another 20% showed early changes suggestive of osteophytes. This was distinct from sham knees from the lean mice, which did not display osteophytes, with early changes evident only in less than 20% of knees (Figure 6d). As with progression of cartilage degeneration and loss, more-aggressive osteophyte formation in MLI-injured knees from HF-diet mice is associated with a diabetic metabolic phenotype but does not correlate with degree of weight gain.
The results of this study demonstrate that consumption of a high-fat diet that leads to weight gain and diabetes will accelerate the progression of OA that is initiated by induction of a meniscal ligamentous injury. This effect on OA does not correlate, however, with degree of increase in body mass or exposure to a high-fat diet before injury. Our study draws different conclusions from the early work of Silberberg and Silberberg [31, 32] who established a link between high-fat diets and OA in rodent models more than 50 years ago. In their pioneering work, they documented an increased incidence of OA in aged mice on an HF diet with age end points of 12 to 24 months . Interestingly, a conclusion drawn from their data was that the incidence but not the rate of progression of OA was affected by the HF diet . In our current study, we clearly establish that HF diets can accelerate the progression of OA after a defined OA initiation in a diarthrodial joint. Perhaps the variable time of spontaneous initiation, the long timeline of OA progression in the absence of a severe initiating injury, and the absence of quantitative end points may have contributed to the inability of Silberberg and Silberberg to detect changes in rate of progression in their studies. Alternatively, the effects of the HF diet on mechanisms of OA initiation and progression in aging versus acute injury may be different.
The relative contributions to OA of biomechanical factors resulting from increased body mass versus metabolic dysfunction in the obese and type 2 diabetic population have not been resolved. In humans, a strong correlation has been shown between elevated body mass index (BMI) and OA [21–23]. Biomechanical factors related to this increased body mass have been argued to make critical contributions to OA of the knee [34, 35]. As for metabolic factors, correlations exist between diabetic parameters (hyperglycemia, hyperinsulinemia) and OA [36–39]. Another strong argument for systemic metabolic factors contributing to OA in the obese and diabetic population comes from the increased incidence of OA in the hand, a site not susceptible to the biomechanical overload present in the weight-bearing joints of an obese individual [37, 38]. Logically, detrimental effects of body mass on OA would be a function of both magnitude of body-mass increase and length of exposure to this condition after initiation of OA. Our short-term HF diet group weighed the same as lean controls at the time of injury and gained approximately 6 g over the following 3-month period. In contrast, the long-term HF-diet group weighed more than 11 g more than controls at the time of knee injury and increased the differential to more than 20 g by 3 months. Despite this obvious difference in duration and degree of exposure to increased body mass, the two diet groups had comparable acceleration of OA progression. From our results, we conclude that weight gain does not correlate with progression of OA in our HF-diet mouse model. Silberberg and Silberberg  came to a similar conclusion that increased body weight in response to HF diets does not correlate with the incidence of joint disease in mice. Recently, Griffin et al.  reported the effect of HF diet-induced obesity on spontaneous OA of aging in female mice at 54 weeks of age and concluded that weight gain and loss of Safranin-O cartilage staining or OA severity score, but not cartilage degeneration, were correlated. Their histologic data suggested a modest OA progression with little loss of cartilage. Perhaps the early stages of OA initiation and progression are more strongly influenced by body mass. As cartilage degeneration becomes more severe, as in our MLI model, a high-fat diet continues to accelerate progression, and in this phase of the disease, the associated metabolic dysfunction becomes more important.
Silberberg and co-workers  did not investigate the metabolic dysfunction in their mouse models as a result of HF diets, but they did observe that the C57BL/6 strain but not the DBA strain was susceptible to increased OA of aging when on HF diets, despite weight gain in both strains. Sokoloff et al. [43, 44] also observed that OA in the DBA strain was not altered by diet, despite weight gain. Recently, Griffin et al.  reported that markedly obese leptin-deficient mice do not have an increased incidence of OA. These observations provide further evidence that factors other than increased body mass are critical to the changes in OA in C57BL/6 mice. Interestingly, C57BL/6 mice are well known for their susceptibility to diabetic changes (hyperinsulinemia, hyperglycemia) when placed on HF diets, whereas DBA mice are resistant to these metabolic changes [29, 46]. Although no cause and effect has been established, these observations show an association between development of a diabetic phenotype and accelerated progression of OA in the C57BL/6 mouse model.
In the mouse, metabolic changes in response to HF diets appear to be important in mediating osteoarthritic pathogenesis. Saturated fat diets derived from animal fat (lard) are most effective in mediating OA changes [31, 44]. They are also more effective than dietary sugar in generating obesity and diabetes in experimental mice . N-3 polyunsaturated fat (PUFA), such as linolenic acid, decreases the detrimental effects of the lard diet  and decrease expression and activity of proteoglycan-degrading enzymes and expression of inflammatory cytokines in articular chondrocyte cultures [49, 50]. As a potential mechanism of action, the n-3 or omega-3 PUFAs that are found in fish oils have been shown to have anti-inflammatory effects with multiple mechanisms of action being proposed . Importantly, one PUFA, eicosapentaenoic acid, has recently been shown to prevent and reverse insulin resistance in mice fed an HF diet . The mechanism of this latter effect has been proposed to be suppression of adipose tissue inflammation . These results suggest that HF diets mediate their effects on both OA and the diabetic phenotype, at least in part through inflammatory effects.
In relation to OA, the observation that obesity is a proinflammatory state may have critical implications for explaining both the increased progression of OA in our mouse model of obesity/type 2 diabetes and the epidemiologic data linking obesity to OA. The proinflammatory state of obesity may synergize with other OA-promoting pathways to accelerate the progression of the cartilage destruction. Thus, our laboratory is currently investigating the contribution of systemic inflammation to OA progression in obesity as a step toward elucidating novel candidate mechanisms that underlie the deleterious effect of the HF diet on the degenerative process.
The results of this study indicate that an HF diet accelerates progression of OA in the C57BL/6 mouse diabetic model after a meniscal ligamentous injury, as assessed by both cartilage degeneration and osteophyte production. Degree of weight gain does not correlate with these changes, and prior exposure to the HF diet is not necessary for these effects. This suggests that metabolic dysregulation in type 2 diabetes is a comorbid factor in the progression of osteoarthritis, and its effect is in addition to that of obesity-related increased weight bearing in afflicted joints.
c-Jun N-terminal kinase
Osteoarthritis Research Society International
polyunsaturated fatty acid.
Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature. 2001, 414: 782-787. 10.1038/414782a.
Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF: Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010, 8: 29-10.1186/1478-7954-8-29.
Huang ES, Basu A, O'Grady M, Capretta JC: Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009, 32: 2225-2229. 10.2337/dc09-0459.
Arthritis as a potential barrier to physical activity among adults with diabetes: United States, 2005 and 2007. MMWR Morb Mortal Wkly Rep. 2008, 57: 486-489.
Dunbar MJ, Howard A, Bogoch ER, Parvizi J, Kreder HJ: Orthopaedics in 2020: predictors of musculoskeletal need. J Bone Joint Surg Am. 2009, 91: 2276-2286. 10.2106/JBJS.H.01521.
Fehring TK, Odum SM, Griffin WL, Mason JB, McCoy TH: The obesity epidemic: its effect on total joint arthroplasty. J Arthroplasty. 2007, 22: 71-76.
Bourne R, Mukhi S, Zhu N, Keresteci M, Marin M: Role of obesity on the risk for total hip or knee arthroplasty. Clin Orthop Relat Res. 2007, 465: 185-188.
Guilak F, Fermor B, Keefe FJ, Kraus VB, Olson SA, Pisetsky DS, Setton LA, Weinberg JB: The role of biomechanics and inflammation in cartilage injury and repair. Clin Orthop Relat Res. 2004, 423: 17-26.
Griffin TM, Guilak F: Why is obesity associated with osteoarthritis? Insights from mouse models of obesity. Biorheology. 2008, 45: 387-398.
Sandell LJ: Obesity and osteoarthritis: is leptin the link?. Arthritis Rheum. 2009, 60: 2858-2860. 10.1002/art.24862.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003, 112: 1821-1830.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112: 1796-1808.
Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007, 117: 175-184. 10.1172/JCI29881.
Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002, 87: 2084-2089. 10.1210/jc.87.5.2084.
Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993, 259: 87-91. 10.1126/science.7678183.
Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 2005, 54: 3458-3465. 10.2337/diabetes.54.12.3458.
Hamilton JS, Powell LA, McMaster C, McMaster D, Trimble ER: Interaction of glucose and long chain fatty acids (C18) on antioxidant defences and free radical damage in porcine vascular smooth muscle cells in vitro. Diabetologia. 2003, 46: 106-114.
Schrauwen P, Hesselink MK: Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes. 2004, 53: 1412-1417. 10.2337/diabetes.53.6.1412.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes. 2003, 52: 1-8. 10.2337/diabetes.52.1.1.
Henriksen EJ, Diamond-Stanic MK, Marchionne EM: Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med. 2011, 51: 993-999. 10.1016/j.freeradbiomed.2010.12.005.
Cicuttini FM, Baker JR, Spector TD: The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol. 1996, 23: 1221-1226.
Lohmander LS, Gerhardsson de Verdier M, Rollof J, Nilsson PM, Engstrom G: Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study. Ann Rheum Dis. 2009, 68: 490-496. 10.1136/ard.2008.089748.
Oliveria SA, Felson DT, Cirillo PA, Reed JI, Walker AM: Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology. 1999, 10: 161-166. 10.1097/00001648-199903000-00013.
Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T, Uchida M, Ogata N, Seichi A, Nakamura K, Kawaguchi H: Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage. 2005, 13: 632-641. 10.1016/j.joca.2005.03.004.
Sampson ER, Beck CA, Ketz J, Canary KL, Hilton MJ, Awad H, Schwarz EM, Chen D, O'Keefe RJ, Rosier RN, Zuscik MJ: Establishment of an index with increased sensitivity for assessing murine arthritis. J Orthop Res. 2011, 29: 1145-1151. 10.1002/jor.21368.
Glasson SS, Blanchet TJ, Morris EA: The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007, 15: 1061-1069. 10.1016/j.joca.2007.03.006.
Glasson SS, Chambers MG, Van Den Berg WB, Little CB: The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage. 2010, 18 (Suppl 3): S17-23.
Wu Q, Kim KO, Sampson ER, Chen D, Awad H, O'Brien T, Puzas JE, Drissi H, Schwarz EM, O'Keefe RJ, Zuscik MJ, Rosier RN: Induction of an osteoarthritis-like phenotype and degradation of phosphorylated Smad3 by Smurf2 in transgenic mice. Arthritis Rheum. 2008, 58: 3132-3144. 10.1002/art.23946.
Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN: Diet-induced type II diabetes in C57BL/6J mice. Diabetes. 1988, 37: 1163-1167. 10.2337/diabetes.37.9.1163.
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008, 31: 1473-1478. 10.2337/dc08-0545.
Silberberg M, Silberberg R: Osteoarthrosis in mice fed diets enriched with animal or vegetable fat. Arch Pathol. 1960, 70: 385-390.
Silberberg R, Silberberg M: Skeletal growth and articular changes in mice receiving a high-fat diet. Am J Pathol. 1950, 26: 113-131. incl 114 pl
Silberberg M, Silberberg R: Degenerative joint disease in mice fed a high-fat diet at various ages. Exp Med Surg. 1952, 10: 76-87.
Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD: The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA. 2001, 286: 188-195. 10.1001/jama.286.2.188.
Felson DT, Goggins J, Niu J, Zhang Y, Hunter DJ: The effect of body weight on progression of knee osteoarthritis is dependent on alignment. Arthritis Rheum. 2004, 50: 3904-3909. 10.1002/art.20726.
Silveri F, Brecciaroli D, Argentati F, Cervini C: Serum levels of insulin in overweight patients with osteoarthritis of the knee. J Rheumatol. 1994, 21: 1899-1902.
Dahaghin S, Bierma-Zeinstra SM, Koes BW, Hazes JM, Pols HA: Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study. Ann Rheum Dis. 2007, 66: 916-920. 10.1136/ard.2005.045724.
Douloumpakas I, Pyrpasopoulou A, Triantafyllou A, Sampanis C, Aslanidis S: Prevalence of musculoskeletal disorders in patients with type 2 diabetes mellitus: a pilot study. Hippokratia. 2007, 11: 216-218.
Hart DJ, Doyle DV, Spector TD: Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol. 1995, 22: 1118-1123.
Silberberg M: Effects of a high fat diet on the joints of aging mice. Arch Pathol. 1950, 50: 828-846.
Griffin TM, Fermor B, Huebner JL, Kraus VB, Rodriguiz RM, Wetsel WC, Cao L, Setton LA, Guilak F: Diet-induced obesity differentially regulates behavioral, biomechanical, and molecular risk factors for osteoarthritis in mice. Arthritis Res Ther. 2010, 12: R130-10.1186/ar3068.
Silberberg M, Silberberg R: Role of thyroid hormone in the pathogenesis of joint disease in mice: effects of radiothyroidectomy and high-fat diets. J Bone Joint Surg Am. 1955, 37-A: 537-548.
Sokoloff L, Mickelsen O, Silverstein E, Jay GE, Yamamoto RS: Experimental obesity and osteoarthritis. Am J Physiol. 1960, 198: 765-770.
Sokoloff L, Mickelsen O: Dietary fat supplements, body weight and osteoarthritis in Dba-2jn mice. J Nutr. 1965, 85: 117-121.
Griffin TM, Huebner JL, Kraus VB, Guilak F: Extreme obesity due to impaired leptin signaling in mice does not cause knee osteoarthritis. Arthritis Rheum. 2009, 60: 2935-2944. 10.1002/art.24854.
Surwit RS, Seldin MF, Kuhn CM, Cochrane C, Feinglos MN: Control of expression of insulin resistance and hyperglycemia by different genetic factors in diabetic C57BL/6J mice. Diabetes. 1991, 40: 82-87. 10.2337/diabetes.40.1.82.
Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, Rebuffe-Scrive M: Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism. 1995, 44: 645-651. 10.1016/0026-0495(95)90123-X.
Silberberg M, Silberberg R, Orcutt B: Modifying effect of linoleic acid on articular aging and osteoarthrosis in lard-fed mice. Gerontologia. 1965, 11: 179-187. 10.1159/000211491.
Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B: n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem. 2000, 275: 721-724. 10.1074/jbc.275.2.721.
Curtis CL, Rees SG, Cramp J, Flannery CR, Hughes CE, Little CB, Williams R, Wilson C, Dent CM, Harwood JL, Caterson B: Effects of n-3 fatty acids on cartilage metabolism. Proc Nutr Soc. 2002, 61: 381-389. 10.1079/PNS2002174.
Chapkin RS, Kim W, Lupton JR, McMurray DN: Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids. 2009, 81: 187-191. 10.1016/j.plefa.2009.05.010.
Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, Lichtenstein AH, Moustaid-Moussa N: Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr. 2010, 140: 1915-1922. 10.3945/jn.110.125732.
The authors thank Ryan Tiernay, Nanette Alcock, and Sarah Mack for processing and sectioning of tissue samples; and Michael Thullen for performing micro-CT analyses. This work was supported by an Arthritis Investigator Award from the Arthritis Foundation (MJZ), NIH R01 AR045700 (RNR), NIH P50 AR 054041 (RNR), and the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center (RAM).
The authors declare that they have no competing interests.
RAM and MJZ conceived the study. RAM participated in the design and coordination of the experiments, carried out the animal studies, and drafted the manuscript. ERS performed the animal surgeries, participated in the scoring of histology slides and the coordination of the study, and helped draft the manuscript. JL performed the tissue processing, histology, histomorphometry, and data analysis. RNR participated in the design and data analysis. MJZ participated in the design and coordination of the experiments, participated in histologic scoring, and helped draft the manuscript. All authors read and approved the final manuscript.